Brief: BerGenBio Announces Top Line Data From Phase II Trial Assessing Bemcentinib In Hospitalised COVID-19 Patients

Oncoinvent ASA

18/05/2021 06:06

May 18 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO ANNOUNCES TOP LINE DATA FROM PHASE II TRIAL
ASSESSING
BEMCENTINIB IN HOSPITALISED COVID-19 PATIENTS
    * TRIAL BGBC020 SHOWS THAT BEMCENTINIB HAS POTENTIAL TO
INCREASE
RATE OF VENTILATOR FREE SURVIVAL IN MORE THAN 50% OF
HOSPITALISED COVID-19 PATIENTS

Source text for Eikon:  ID:nWkrnhSrG 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))